KCTD15 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ro 25-6981 maleate | 1312991-76-6 | sc-204887 sc-204887A sc-204887B | 1 mg 10 mg 50 mg | $107.00 $227.00 $930.00 | ||
Ro 25-6981 is a selective NMDA receptor antagonist that blocks NMDA receptor subunits which are indirectly involved with the neural pathways that KCTD15 is associated with, leading to inhibition of KCTD15's influence on neuronal signaling. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB-216763 is a potent inhibitor of GSK-3beta, a kinase involved in Wnt signaling. KCTD15's role in the development of neuronal tissues is influenced by Wnt signaling, thus inhibition of GSK-3beta can suppress the pathways KCTD15 is involved in. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor that affects cytoskeletal dynamics. Since KCTD15 is known to be involved in processes that are related to cell morphology, inhibition of ROCK can lead to the functional suppression of KCTD15's role in these processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. KCTD15 has been implicated in the MAPK signaling pathway, and inhibition of MEK would attenuate the pathway's activity, thereby inhibiting KCTD15's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which prevents AKT activation. As KCTD15 is involved in pathways that are influenced by AKT signaling, inhibition of PI3K would decrease AKT activity, thereby inhibiting KCTD15's associated functions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, serving the same function as LY294002 by inhibiting AKT-mediated signaling pathways that KCTD15 is involved in, leading to a functional inhibition of KCTD15. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, thereby preventing the activation of ERK1/2 in the MAPK pathway. Since KCTD15 is connected to MAPK signaling, inhibition of this pathway would lead to a functional inhibition of KCTD15. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. Inhibition of JNK would affect the signaling pathways that KCTD15 is associated with, leading to its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which by inhibiting p38, affects cellular responses in which KCTD15 is involved, leading to functional inhibition of the protein's role in these processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the PI3K/AKT pathway, and since KCTD15 is implicated in pathways regulated by mTOR, inhibition by Rapamycin would result in functional inhibition of KCTD15. | ||||||